Clinical Trials
14 trialsNCT05486481 2025-03-06
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
University of California, San Francisco
Phase 1/2 Withdrawn
NCT06050512 2024-11-19
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
University of Pittsburgh
Phase 1/2 Withdrawn
NCT05647512 2023-11-18
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
LaNova Medicines Limited
Phase 1/2 Withdrawn
NCT03701321 2023-09-26
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT05408026 2023-01-27
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Alliance Foundation Trials, LLC.
Phase 1/2 Withdrawn
NCT05493618 2023-01-27
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Hackensack Meridian Health
Phase 1/2 Withdrawn
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn
NCT03856112 2019-03-26
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT02802163 2017-04-25
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn
NCT02605356 2016-10-07
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Bayer
Phase 1/2 Withdrawn
NCT02862145 2016-09-27
MRX34-102
Mirna Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT00776802 2013-06-25
GCS-100LE
La Jolla Pharmaceutical Company
Phase 1/2 Withdrawn